Why ProKidney Corp.’s (PROK) Stock Is Up 5.28%
As of Tuesday, August 25, ProKidney Corp.’s PROK share price has surged by 5.28%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Commentary & Analysis
Why ProKidney Corp.’s (PROK) Stock Is Up 9.15%
As of Friday, August 21, ProKidney Corp.’s PROK share price has surged by 9.15%, which has investors questioning if this is right time to sell.Jenna Brashear
Why ProKidney Corp.’s (PROK) Stock Is Down 5.34%
As of Friday, August 14, ProKidney Corp.’s PROK share price has dipped by 5.34%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why ProKidney Corp.’s (PROK) Stock Is Down 6.52%
As of Wednesday, August 12, ProKidney Corp.’s PROK share price has dipped by 6.52%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why ProKidney Corp.’s (PROK) Stock Is Down 9.17%
As of Tuesday, August 11, ProKidney Corp.’s PROK share price has dipped by 9.17%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | PROK | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $399.1 | $288.9 | 34% |
|
| Shares Out (Mil) | 186.6 | 54.0 | 75% |
|
| Institutional Ownership | 58.9% | 93.1% | 38% |
|
| Float (Mil) | 160.5 | 41.4 | 70% |
|
| Beta | 1.72 | 0.94 | 87% |
|
| Avg Daily Volume (000s) | 1,073 | 480 | 73% |
|
| Price Change (52-week) |
(17.0%) | 59.9% | 32% |
|
| Growth | PROK | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (20.9%) | (10.1%) | 19% |
|
| EPS (5yr) | (15.1%) | 15.9% | 18 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | 22.0% | (15.6%) | 81% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 5 | |
| Current EPS | ($0.140) | ($0.562) | ($0.586) | |
| Month Ago EPS | ($0.141) | ($0.538) | ($0.576) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.141) | ($0.538) | ($0.576) | |
| Year/Year Chg | (7.9%) | 9.1% | (25.4%) | |
| Financials | PROK | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $37 | 2% |
|
| Net Income (TTM) (Mil) | ($84) | ($43) | 12% |
|
| EPS (TTM) | ($0.557) | ($1.500) | 27% |
|
| Operating Cash Flow (TTM) (Mil) | ($141) | ($31) | 5% |
|
| Net Cash Flow (TTM) (Mil) | ($10) | $2 | 30% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $4 | 21% |
|
| Enterprise Value (Q1) (Mil) | $1,265 | $190 | 43% |
|
| Valuation | PROK | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.84 | na |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | PROK | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 66.9% | 96% |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (27.1%) | (47.7%) | 18% |
|
| ROE | 8.9% | (55.0%) | 54% |
|
| Liabilities to Assets | 10.5% | 29.6% | 6% |
|
| F-Score | 2 | 3 | 7% |
|
ProKidney Corp. did not pass any screens on 9/2/2026.
